The Oncology Institute and House Rx entered into a multi-year relationship that will integrate House Rx’s specialty medication dispensing model to operate and manage TOI‘s clinic and pharmacy locations in multiple markets. House Rx provides clinics with specialized technology and services support from pharmacists and care coordinators. House Rx staff are integrated with the clinic to help patients start therapy as quickly as possible and drive adherence to treatment for better outcomes. TOI’s alignment with House Rx will expand patient access to oral specialty medications via TOI dispensary and pharmacy locations, and enhance in-office dispensary operations. The relationship will further enable TOI to provide convenient and affordable access to value-based therapies for patients as part of its comprehensive community-based care model.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TOI:
- The Oncology Institute Announces Second Quarter 2023 Earnings Release Date and Conference Call
- The Oncology Institute price target lowered to $2 from $3 at Guggenheim
- TOI Skyrockets on Teaming Up with Massive Bio on Advancing Cancer Care with AI
- The Oncology Institute (TOI) and Massive Bio Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research
- The Oncology Institute to Open Project Southland